Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine

Mercado, Mónica Vázquez-Del; Muñoz-Valle, J.F.; Santos, Arturo; Bernard-Medina, Ana Guilaisne; Martínez-Bonilla, Gloria; Paczka, Jose A; Ruiz‐Garcia, Henry; Orozco-Alcalá, José Javier; Orozco‐Barocio, Gerardo; Quezada-Arellano, D; Gurrola-Díaz, Carmen M.; Nuño-González, Patricia; Best-Aguilera, Carlos; Chávez-Castellanos, R; Panduro, Arturo

doi:10.1080/030097402317255345

Cited by 4 publications

(2 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary focus of other clinical trials regarding cardiovascular disease and chloroquine-derived medications revolves around lipids. Three studies involving rheumatic patients found those receiving HCQ had a noticeable benefit in their lipid profiles including a decrease in total cholesterol, low-density lipoproteins (LDL), and apolipoprotein B [188][189][190]. Three additional studies between 2013 and 2015 focused also on chloroquine's influence on both lipid levels and insulin sensitivity.…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer

et al. 2022

View full text Add to dashboard Cite

Chloroquine (CQ) and Hydroxychloroquine (HCQ), initially utilized in the treatment of malaria, have now developed a long list of applications. Despite their clinical relevance, their mechanisms of action are not clearly defined. Major pathways by which these agents are proposed to function include alkalinization of lysosomes and endosomes, downregulation of C-X-C chemokine receptor type 4 (CXCR4) expression, high-mobility group box 1 protein (HMGB1) inhibition, alteration of intracellular calcium, and prevention of thrombus formation. However, there is conflicting data present in the literature. This is likely the result of the complex overlapping pathways between these mechanisms of action that have not previously been highlighted. In fact, prior research has focused on very specific portions of particular pathways without describing these in the context of the extensive CQ/HCQ literature. This review summarizes the detailed data regarding CQ/HCQ’s mechanisms of action while also providing insight into the overarching themes. Furthermore, this review provides clinical context to the application of these diverse drugs including their role in malaria, autoimmune disorders, cardiovascular disease, thrombus formation, malignancies, and viral infections.

show abstract

Section: Cardiovascular Diseasementioning

confidence: 99%

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Many studies have reported that the favorable effects of CQ on serum lipid levels manifested by; reducing LDL-C, total cholesterol (TC), increasing in high-density lipoprotein (HDL-C), and decreasing in triglyceride level (TGs) [134] [135] [136] [137]. Reduction of Apolipoprotein b lipoprotein is investigated through using this agent as a treatment with RA and SEL treated patients [138]. One of them indicates that because it is a weak base compound, that makes it able to accumulate in high amount inside the acid intracellular organelles such as lysosomes [139] and cause a reduction in secretion of VLDL which is one of a lysosomal function.…”

Section: Mechanism Of Anti-lipidemic Effectmentioning

confidence: 99%

Wide Applications of Chloroquine Other Than Antimalarial

Alani¹,

Alwash²,

Ibrahim³

2020

View full text Add to dashboard Cite

Chloroquine (CQ) was and still considered as the most common agent in the treatment and prophylaxis of malaria, it also possesses many different pharmacological and biological activities that make it able to be used as a therapy or adjuvant therapy for many types of diseases. CQ exhibits anticancer activity alone or as adjuvants with other agents against many kinds of tumors. Its activities also were approved as an anti-inflammatory agent in rheumatoid and other autoimmune diseases like systemic lupus and rheumatic arthritis. Its' important role in the improvement of many metabolic disorders like hypertension, hyperglycemia, and lipid profile disturbances was also established. CQ can act against different microbial infections such as many types of viruses, bacteria and fungus by different mechanisms of action. Furthermore, its dermatological role in the treatment of many skin diseases was demonstrated. Recently, CQ showed a very responsive role in curing and prevention of the covoid-19 virus. This review summarizes intensively the multiple therapeutic applications of CQ and discusses the possible mechanisms of action for these applications.

show abstract

Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features

et al. 2006

View full text Add to dashboard Cite

We investigate the clinical association of tumor necrosis factor receptor 2 (TNFR2) M196R polymorphism with rheumatoid arthritis (RA) and knee osteoarthritis (OA). Acute phase reactants, lipid profile, sTNFR2 levels, disease activity-disability indexes, and TNFR2 M196R polymorphism were analyzed in 50 RA, 50 knee OA patients, and 120 healthy subjects (HS). The M/M genotype frequency was 0.74 (RA), 0.80 (OA), and 0.64 (HS). The M/R genotype frequency was RA (0.26), OA (0.20), and HS (0.29). The R/R genotype was observed only in HS (0.07). The M allele was associated with OA (P = 0.0137, OR = 2.43). Total cholesterol, triglyceride levels, apolipoprotein A-I and B showed significant differences (P < 0.05). The highest sTNFR2 levels were observed in RA and OA (P = 0.001), however M/M and M/R carriers do not correlate with sTNFR2 production. Our findings suggest an association of the M allele with knee OA. In addition, high sTNFR2 levels in RA and OA were found.

show abstract

Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine

Abstract: Reduced apo B levels were observed associated to chloroquine treatment and 2/3 APO E genotype.

Cited by 4 publications

References 5 publications

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer

Wide Applications of Chloroquine Other Than Antimalarial

Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features

Contact Info

Product

Resources

About